Trial ID or NCT#

NCT00725946

Status

not recruiting iconNOT RECRUITING

Purpose

This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and methimazole (impedes organification). Tumor, organ and whole body dosimetry will be calculated in each patient.

Official Title

A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Michael L. Goris
Robert W. Carlson
Laurence Katznelson, MD
Laurence Katznelson, MD
Neuroendocrinologist, Endocrinologist
Professor of Neurosurgery and of Medicine (Endocrinology)
Iris C. Gibbs, MD, FACR, FASTRO
Iris C. Gibbs, MD, FACR, FASTRO
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Sanjiv Sam Gambhir, MD, PhD
Lawrence Recht, MD
Lawrence Recht, MD
Neuro-oncologist
Professor of Neurology and, by courtesy, of Neurosurgery

Contact us to find out if this trial is right for you.

CONTACT

Marilyn Florero
(650) 724-1953